CONTEXT: Serum testosterone measurement has no widely accepted place in the management of patients with prostate cancer (PCa). However, several potential clinical applications of serum testosterone determination can be envisaged. OBJECTIVE: To review the role of testosterone and the androgen axis in the natural history of PCa and evaluate the evidence for the clinical application of serum testosterone measurement in patient screening, diagnosis, and management. EVIDENCE ACQUISITION: A Medline search retrieved original research and review articles relating to the androgen axis in PCa and the use of testosterone measurement for (1) assessing PCa risk in the general population, (2) adding to the specificity of prostate-specific antigen (PSA) testing, (3) determining tumour aggressiveness, (4) assessing the efficacy of androgen-deprivation therapy (ADT), and (5) optimising the scheduling of intermittent ADT. Relevant data were reviewed during a roundtable discussion, and consensus recommendations were agreed. EVIDENCE SYNTHESIS: A body of data implicates the androgen axis in PCa throughout its natural history. Based on current evidence, serum testosterone measurement cannot be recommended for determining PCa risk, increasing specificity of PSA testing, or assessing tumour aggressiveness. In contrast, for patients receiving ADT, there is a clear rationale for serum testosterone monitoring to ensure that castration levels are achieved. Practical recommendations for testosterone measurement during ADT are outlined. If PSA is rising while on ADT, castration levels of serum testosterone must be demonstrated before hormonal independence can be assumed. Serum testosterone levels might be considered an additional trigger for therapy reinitiation in intermittent ADT schedules. Finally, future prospective studies should further evaluate the potential relevance of testosterone measurement as an independent assessment of prognosis and treatment decision in different disease stages. CONCLUSIONS: As a therapeutic target, serum testosterone levels should be monitored to verify response to ADT and confirm suspected castration independence. Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
CONTEXT: Serum testosterone measurement has no widely accepted place in the management of patients with prostate cancer (PCa). However, several potential clinical applications of serum testosterone determination can be envisaged. OBJECTIVE: To review the role of testosterone and the androgen axis in the natural history of PCa and evaluate the evidence for the clinical application of serum testosterone measurement in patient screening, diagnosis, and management. EVIDENCE ACQUISITION: A Medline search retrieved original research and review articles relating to the androgen axis in PCa and the use of testosterone measurement for (1) assessing PCa risk in the general population, (2) adding to the specificity of prostate-specific antigen (PSA) testing, (3) determining tumour aggressiveness, (4) assessing the efficacy of androgen-deprivation therapy (ADT), and (5) optimising the scheduling of intermittent ADT. Relevant data were reviewed during a roundtable discussion, and consensus recommendations were agreed. EVIDENCE SYNTHESIS: A body of data implicates the androgen axis in PCa throughout its natural history. Based on current evidence, serum testosterone measurement cannot be recommended for determining PCa risk, increasing specificity of PSA testing, or assessing tumour aggressiveness. In contrast, for patients receiving ADT, there is a clear rationale for serum testosterone monitoring to ensure that castration levels are achieved. Practical recommendations for testosterone measurement during ADT are outlined. If PSA is rising while on ADT, castration levels of serum testosterone must be demonstrated before hormonal independence can be assumed. Serum testosterone levels might be considered an additional trigger for therapy reinitiation in intermittent ADT schedules. Finally, future prospective studies should further evaluate the potential relevance of testosterone measurement as an independent assessment of prognosis and treatment decision in different disease stages. CONCLUSIONS: As a therapeutic target, serum testosterone levels should be monitored to verify response to ADT and confirm suspected castration independence. Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Authors: Hui Zhou; Yuesong Wang; Matthew Gatcombe; Jacob Farris; Julianne C Botelho; Samuel P Caudill; Hubert W Vesper Journal: Anal Bioanal Chem Date: 2017-08-11 Impact factor: 4.142
Authors: Laurence Klotz; Bobby Shayegan; Chantal Guillemette; Loretta L Collins; Geoffrey Gotto; Dominique Guérette; Marie-Paule Jammal; Tom Pickles; Patrick O Richard; Fred Saad Journal: Can Urol Assoc J Date: 2017-12-19 Impact factor: 1.862
Authors: Kyle O Rove; E David Crawford; Massimo Perachino; Juan Morote; Laurence Klotz; Paul H Lange; Gerald L Andriole; Alvin M Matsumoto; Samir S Taneja; Mario A Eisenberger; Leonardo O Reis Journal: Urology Date: 2014-04-06 Impact factor: 2.649
Authors: Daniel Keizman; Peng Huang; Emmanuel S Antonarakis; Victoria Sinibaldi; Michael A Carducci; Samuel Denmeade; Jenny J Kim; Janet Walczak; Mario A Eisenberger Journal: Prostate Date: 2011-03-22 Impact factor: 4.104